Altimmune's GLP-1/glucagon data in alcoholism Read in browser

Thank you for reading, dupa dupackia! basic Subscription UPGRADE

M Tue W Th F 28 July, 2026

sponsored by Medicine is a national security asset. America wins by building, not retreating. Adversary states are investing to control the biopharmaceutical capacity that national security now depends on. China already hosts 39 percent of the world's clinical trials. America cannot afford to surrender leadership of this strategic industry. But tariffs, decoupling, and blanket bans are not toughness. They are retreat. America wins by building capacity at home and with trusted allies, and by out-competing rivals instead of hiding from them. See where we stand

news GSK to start three-year plan to save cash, takes £1.33B hit on cough trial failure Altimmune’s GLP-1-based shot cuts drinking in patients with alcoholism Capricor shares plunge after FDA says DMD therapy lacks efficacy ahead of adcomm

Jul 30 1:00 pm ET Accelerating Phase 1 decisions with liquid biopsy: From early signals to actionable insights sponsored by GUARDANT Aug 19 1:00 pm ET From pilots to production: AI across R&D, safety, regulatory, and clinical sponsored by IBM

Associate Director / Director, Preclinial Development - Immunology Terray Therapeutics, Inc. Monrovia, CA, USA Senior Director, Licensing Officer Bayer Cambridge, MA, USA Machine Learning Researchers and Engineers D. E. Shaw Research New York, NY, USA Scientist, Drug Discovery Data for AI/ML D. E. Shaw Research New York, NY, USA Recruit talent with Endpoints Careers Contact Meg Estacio: mestacio@endpointsnews.com

A year into the tariff era, the biopharma industry has stopped bracing for impact — however manufacturing and supply chain leaders are still rewriting their plans on the fly. We’re bringing together the experts tracking what R&D logistics looks like today. Join us — find out what’s next.

ENDPOINTS PHARMA Updated: AstraZeneca foresees blockbuster sales for Claudin 18.2 ADC, but Ultomiris flops in rare disease •  AstraZeneca looks to AI to ease risk in late-stage trials, speed up filings Six wellness peptides win backing from FDA advisory committee, setting up future agency action Virginia federal judge says FDA should reconsider mifepristone restrictions The patent cliff is looming and CDMOs need to be prepared, Fujifilm CEO says

in case you missed it 1. Sarepta turns to Michael Severino as CEO, looking to move past recent turmoil 2. Updated: Argenx to pick up autoimmune biotech Forte Biosciences for $2.2B 3. Exclusive: Schrödinger CEO 'couldn't be more pleased to be wrong' in launch of AI agent Bunsen 4. Legend CEO Ying Huang resigns; Carvykti chief named interim leader